Clinuvel Pharmaceuticals Limited (OTCMKTS:CLVLY) Short Interest Update

Clinuvel Pharmaceuticals Limited (OTCMKTS:CLVLY) saw a significant growth in short interest in the month of January. As of January 15th, there was short interest totalling 12,200 shares, a growth of 144.0% from the December 31st total of 5,000 shares. Based on an average daily trading volume, of 5,300 shares, the days-to-cover ratio is presently 2.3 days.

Clinuvel Pharmaceuticals Stock Performance

Shares of CLVLY traded down $0.02 on Thursday, reaching $7.65. The stock had a trading volume of 2,206 shares, compared to its average volume of 3,206. Clinuvel Pharmaceuticals has a twelve month low of $6.80 and a twelve month high of $11.40. The firm has a 50-day moving average of $7.80 and a 200 day moving average of $8.94.

Clinuvel Pharmaceuticals Company Profile

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP).